Neurotoxicity Evaluation of Beta-lactams in Intensive Care Unit and Identification of the Risk Factors

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03628300

Acronym

NebuLar

Enrollment

400

Registered

2018-08-14

Start date

2017-01-01

Completion date

2017-07-01

Last updated

2026-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Kidney Injury, Beta Lactams, Critical Care, Neurotoxicity, Sepsis, Therapeutic Drug Monitoring

Keywords

neurotoxicity, Sepsis, beta lactams, therapeutic drug monitoring, critical care, Acute Kidney Injury

Brief summary

Beta-lactams are the most prescribed antibiotics in intensive care units. The lack of linearity between the dose administered and the exposition due to the very high variability of the pharmacokinetics in critically ill patients requires that the treatment be adapted on a case-by-case basis depending on the drug serum concentration. However, maximum concentrations not to be exceeded in order to limit beta-lactams toxicity are generally unknown. The main toxic risk of beta-lactams in intensive care is indeed neurological, but the neurotoxicity is probably underdiagnosed due to the variability of the signs observed, their time to onset, and confounding factors. Apart from recommendations for dose adjustment in the event of renal insufficiency, the procedures for the proper use of beta-lactams in intensive care are poorly established. The study presented here aims to assess the impact of the neurotoxic risk of beta-lactams in intensive care based on therapeutic drug monitoring, and thus to improve beta-lactam safety in critically ill patients. This is a prospective cohort study evaluating change in neurological status of patients admitted to the ICU and treated with a beta-lactam antibiotic with therapeutic drug monitoring. Neurological evaluation and scoring (Glasgow scale, CAM-ICU, Richmond agitation-sedation scale) and beta-lactam serum concentration assay are performed together 2 to 3 times a week.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients admitted to the ICU * Treatment initiation by an antibiotic of the beta-lactam class * Beta-lactam therapeutic drug monitoring

Exclusion criteria

* Any neurological disorder already present at admission * Patients on mechanical ventilation who presented a neurological disorder before being intubated and sedated

Design outcomes

Primary

Measure	Time frame	Description
proportion of patients with a change in neurological status	one week	the primary objective is to assess the frequency of beta-lactam neurotoxicity in a standardized use with therapeutic drug monitoring

Secondary

Measure	Time frame	Description
beta-lactam serum concentration according neurological status	one week	beta-lactam serum concentration is assayed by a validated HPLC method

Countries

France

Contacts

PRINCIPAL_INVESTIGATORYoussef BENNIS, PU-PH

CHU AMIENS

Outcome results